- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01375179
Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients
A Multi-centre, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of KRP203 in Subjects With Moderately Active Refractory Ulcerative Colitis
This study is designed as a proof of concept of KRP203 for induction of remission in ulcerative colitis (UC). The purpose of this study is to evaluate clinical benefit of KRP203 in subjects with moderately active refractory ulcerative colitis.
The study will provide safety and tolerability data in this subject population up to eight weeks of treatment with KRP203. Additionally, this study will evaluate the duration of a clinical response to KRP203 by following up responding subjects for an additional 12 weeks.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ulcerative colitis subjects. In total, approximately 72 subjects will be randomized into the study.
After 30 patients have completed the 8 week treatment period with KRP203 or placebo, there will be an interim analysis to determine preliminary efficacy. The study will consist of up to 28 day screening period (day -35 to -8), baseline period (day -7 to day -1), treatment period (day 1 to day 56), follow-up period and study completion.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Gent, Belgien, 9000
- Novartis Investigative Site
-
Leuven, Belgien, 3000
- Novartis Investigative Site
-
-
-
-
-
Bern, Schweiz, 3010
- Novartis Investigative Site
-
Zurich, Schweiz, 8091
- Novartis Investigative Site
-
-
-
-
-
Nottingham, Storbritannien, NG7 2UH
- Novartis Investigative Site
-
-
Oxfordshire
-
Oxford, Oxfordshire, Storbritannien, OX3 9DU
- Novartis Investigative Site
-
-
-
-
-
Stockholm, Sverige, 116 91
- Novartis Investigative Site
-
Stockholm, Sverige, SE-141 86
- Novartis Investigative Site
-
Uppsala, Sverige, 751 85
- Novartis Investigative Site
-
-
-
-
-
Frankfurt am Main, Tyskland, 60318
- Novartis Investigative Site
-
Hamburg, Tyskland, 20148
- Novartis Investigative Site
-
Köln, Tyskland, 51103
- Novartis Investigative Site
-
-
-
-
-
Budapest, Ungern, 1083
- Novartis Investigative Site
-
Debrecen, Ungern, 4032
- Novartis Investigative Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Active disease defined by partial Mayo score and modified Baron score with disease extending at least 25 cm from the anal verge
- Subjects must have inadequately responded or intolerance to 5-ASA therapy
Exclusion Criteria:
- Subjects receiving treatment for UC (other than 5-ASAs and steroids) within the time frame mentioned in protocol
- Past or recent history of significant medical illness and/or clinically significant lab abnormalities including but not limited to hematology, clinical chemistry, urine analysis, ECG abnormalities, HIV, Hepatitis B/C
- Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, ophthalmic, cardiac, blood, renal, hepatic, infectious, psychiatric or any medically unstable condition, as assessed by the primary treating physician which, in the opinion of the investigator, would immunocompromise the subject and/or place the subject at unacceptable risk for participation in a study of an immunomodulatory therapy Other protocol-defined inclusion/exclusion criteria apply
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: Placebo
|
|
Experimentell: KRP203
Experimental Edit Experimental |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in clinical remission rate
Tidsram: 8 weeks
|
Difference between clinical remission rate of subjects on KRP203 versus placebo
|
8 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Tidsram: 8 weeks
|
Safety and tolerability of KRP203 assessed by the number of subjects with adverse events where KRP203 is given as an oral drug for 8 weeks once a day in ulcerative colitis subjects
|
8 weeks
|
Pharmacokinetic properties of KRP203 at steady-state using whole blood samples in patients with ulcerative colitis subjects
Tidsram: 8 weeks
|
8 weeks
|
|
Difference in pharmacokinetic levels
Tidsram: 12 weeks
|
To explore the relationship between KRP203 and KRP203-P pharmacokinetic levels and clinical efficacy outcomes such as the partial Mayo score and endoscopic modified Baron Score
|
12 weeks
|
Assessment of the pharmacodynamic effect of KRP203 on absolute lymphocyte count and leukocyte subsets in ulcerative colitis subjects
Tidsram: 12 weeks
|
12 weeks
|
|
Change in markers of inflammation
Tidsram: 12 weeks
|
Measure of the effect of KRP203 on markers of inflammation, including but not limited to ESR, CRP and fecal calprotectin/ lactoferrin as well as histopathological markers of gut mucosa using biopsy samples in ulcerative colitis subjects
|
12 weeks
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CKRP203A2201
- 2010-019970-33 (EudraCT-nummer)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Ulcerös kolit
-
Michael E Villarreal, MDMerck Sharp & Dohme LLCAvslutadClostridia Difficile Colitis | Clostridium; SepsisFörenta staterna
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...AvslutadULCERATIV KOLITFrankrike, Belgien
-
Nantes University HospitalInstitut National de la Santé Et de la Recherche Médicale, France; Takeda; Mauna Kea TechnologiesAvslutad
-
Jewish General HospitalAvslutadFulminant Clostridium Difficile ColitisKanada
-
University of AlbertaUniversity of British Columbia; McGill University; University of CalgaryAktiv, inte rekryterandeClostridium Difficile Diarré | Clostridia Difficile ColitisKanada
-
University of VirginiaImperial College LondonRekryteringClostridium Difficile-infektion | Clostridium Difficile Diarré | Clostridioides Difficile-infektion | Clostridia Difficile ColitisFörenta staterna
Kliniska prövningar på KRP203
-
Novartis PharmaceuticalsAvslutadSubakut kutan lupus erythematosusGrekland, Tyskland, Italien